ALLR

ALLR

Allarity Therapeutics, Inc.

1.42 USD

Last updated Sep 4, 20:48 UTC

Yesterday HIGH

$1.48

Yesterday LOW

$1.39

52w HIGH

$2.06

52w LOW

$0.77

EPS

-0.21

PE

-6.76

Next Earnings

Nov 13, 2026

Overview News Government Trades Fundamentals

Allarity Therapeutics, Inc. stock is up 6.77% since 30 days ago. The next earnings date is Nov 13, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 4 September’s closed higher than August.

Benzinga Newsdesk

Tue Jun 30, 2026

Allarity Therapeutics Receives U.S. Patent And Trademark Office Patent For Its Drug Response Predictor Companion Diagnostic

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT
Benzinga Insights

Mon Jun 22, 2026

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ:ALLR) stock increased by
Benzinga Newsdesk

Thu Jun 18, 2026

Allarity Therapeutics To Present A Trial-In-Progress Poster At The ESMO Gynaecological Cancers Congress, June 17–19

The poster outlines the scientific background, study design, and clinical rationale for the Company's ongoing Phase 2 trial evaluating stenoparib in patients with advanced platinum-resistant or platinum-ineligible
Benzinga Insights

Wed Jun 10, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Newsdesk

Mon Jun 8, 2026

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $10.25

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.75 to $10.25.
Benzinga Newsdesk

Fri May 15, 2026

Allarity Therapeutics Q1 EPS $(0.17) Beats $(0.22) Estimate, Sales $25.000K

Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 32 percent increase over losses of $(0.25) per share
Benzinga Newsdesk

Tue May 5, 2026

Allarity Therapeutics shares are trading higher after the company announced that its active pharmaceutical ingredient manufacturing campaign for stenoparib is progressing in line with the planned timeline for completion, no later than Q3 of 2026, at its world-class contract development and manufacturing organization.
Benzinga Newsdesk

Tue May 5, 2026

Allarity Therapeutics Says API Manufacturing Campaign For Stenoparib Is Progressing In Line With Planned Timeline For Completion No Later Than Q3 Of 2026 At CDMO

Phase 3 manufacturing campaign on track for completion no later than third quarter 2026, supporting expected pivotal trial in advanced ovarian cancer Supports accelerating stenoparib toward FDA approval following
Benzinga Newsdesk

Mon Apr 27, 2026

Allarity Therapeutics Says USPTO Issues Notice Of Allowance For Patent Application Covering DRP Companion Diagnostic Specific To Stenoparib
Benzinga Newsdesk

Fri Apr 10, 2026

Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $9.75

Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $9.5 to $9.75.

NTLA $12.75 USD

IREN $44.64 USD

NVTS $11.81 USD

MSTX MSTX $16.80 USD

NFLX $78.29 USD

AAPL $319.87 USD

SNDK $1,730.23 USD